Videos

Joy Baker, MD, FACOG, explains how zuranolone's rapid onset gives clinicians a meaningfully different counseling conversation for PPD.

Identifying who is most at risk for endometriosis, and recognizing its hallmark symptoms early, can shorten the path to diagnosis and reduce its enormous economic toll.

Endometriosis affects far more women than commonly cited figures suggest, and the gap between perception and reality shapes how the disease is diagnosed and treated.

Jeffrey Chapa, MD, explains how telehealth and remote monitoring can extend maternal-fetal medicine access.

Damian Alagia, III, MD, attributes gaps in prenatal STI detection and treatment to systemic flaws in access rather than individual clinical judgment.

A scoping review presented at ACOG 2026 by Calbeth C. Alaribe, DMSc, MPH, PA-C, found no studies examining the association between preeclampsia, eclampsia, and endometriosis among Black women.

Damian Alagia, III, MD, joined Contemporary OB/GYN for a discussion on STIs in women, associated stigma, and structural barriers to testing.

Appelbaum frames surgery as one component of endometriosis intervention, stressing ongoing postsurgical treatment given the chronic nature of the disease.

Heather Appelbaum, MD, FACOG, explains how distinguishing clinical from surgical diagnosis of endometriosis can enable earlier intervention, in a discussion of her NASPAG presentation.

According to Beth Ann Clayton, DNP, CRNA, FAANA, FAAN, maintaining patients with substance use disorder on methadone or buprenorphine is a critical component of preoperative planning.

The phase 4 study's oversampling of moderate PPD patients, showing a nearly 9-point EPDS drop by day 15, helps close a gap left by trials that enrolled predominantly severe cases.

Roshni Koli, MD, describes how embedding mental health care within the ob-gyn setting drove high engagement and rapid symptom remission in a perinatal collaborative care study.

A recent mediation analysis shows 54% of elinzanetant's (Lynkuet) sleep benefit is independent of nighttime VMS reduction, suggesting NK1 blockade targets menopausal sleep disruption through a distinct pathway.

A retrospective study found that a tech-enabled perinatal collaborative care program delivered within an OB/GYN practice was associated with reductions in depression and anxiety symptoms.

Progress slowed in 120 of 204 countries during 2015–2023 versus 2000–2015, explains Maegan Ashworth Dirac, MD, PhD, who attributes the largest gains to either broad development or targeted maternal care investments.

Kate McLean, MD, MPH, FACOG, describes how statistical clustering of more than 15,000 BV-diagnosed patients surfaced distinct microbial subtypes without predefined assumptions.

Kate McLean, MD, MPH, FACOG, describes how metagenomic sequencing and new transmission data are reshaping the understanding of bacterial vaginosis beyond a traditional, oversimplified definition.

Because only one third of nocturnal wakefulness during the menopausal transition is directly linked to hot flashes, VMS-targeted therapies alone are insufficient for many women with sleep disruption—and cognitive behavioral therapy for insomnia, supported by sleep society guidelines and accessible through free digital platforms, should be part of every clinician's sleep management toolkit, according to Pauline M. Maki, PhD.

Stephanie Faubion, MD, and Fiona Baker, PhD, discuss how elinzanetant can play a role in sleep disturbances because of VMS, emerging data on the subject, and how to determine the right candidate for the NK1-3 dual-receptor antagonist.

The vacuum device was favored on three measures: lower ICU admission (5% vs 12%), lower blood transfusion rates (48% vs 62%), and shorter indwelling time (by 1.96 hours), all P <.001.

Key unanswered questions in the management of VMS in patients with breast cancer include the long-term oncologic impact of NK receptor antagonists, the broader role of patient-reported outcomes in guiding therapy selection, and the need for prospective observational studies to evaluate real-world outcomes.

Effective management of VMS in patients with breast cancer requires individualized assessment and shared decision-making, with elinzanetant (Lynkuet) emerging as the preferred pharmacologic option for patients with moderate-to-severe symptoms given its early onset of action, NCCN-preferred status, and the most robust evidence base in this population.

Experts explain the role and safety of Bayer's elinzanetant to treat vasomotor symptoms since its approval in October 2025.

SWAN data from 2066 women demonstrate that sleep disturbance has a greater independent effect on health-related quality of life than VMS alone, with the combination of both symptoms producing the most pronounced impact on physical functioning and energy—findings that support prioritizing sleep as a treatment target alongside vasomotor symptoms in menopausal care, according to Pauline M. Maki, PhD.

Research presented at ACOG suggests that gaps exist in sexual medicine education across Midwestern medical schools, potentially leading to underprepared graduates.

Eduardo Lara-Torre, MD, FACOG, emphasizes that pediatric and adolescent gynecology provides a critical bridge to ensure young patients do not lose access to care as they transition to adult providers.

Shared decision-making around nonhormonal VMS and sleep management requires moving through contraindications, patient preferences, and monitoring burdens together, with elinzanetant's (Lynkuet) dual receptor profile making it a particularly relevant option for women with both VMS and sleep disruption—and with follow-up at 2 to 3 months essential to evaluating response, according to Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF.

Elle Kielar Grevstad, PhD, explains how a 2-MDM panel detected endometrial cancer in self-collected vaginal fluid with 96% sensitivity and 82% specificity, according to a marker reduction study published in Gynecologic Oncology.

Jessia Gaulton, MD, MPH, speaks to knowledge and gaps surrounding the menopause transition and mental health associations, while highlighting new Menopause Hub resources from FamilyWell Health.

An analysis from OASIS-4 demonstrated that elinzanetant (Lynkuet) consistently improved sleep disturbance and menopause-related quality of life across all endocrine therapy subgroups—with patients transitioning from moderate to normal sleep disturbance range by week 12—and that these benefits were sustained through 52 weeks.